The recent AUA meetings in Atlanta had a number of interesting abstracts presented that concern men with advanced prostate cancer. Some of the more interesting abstracts were look back analysis of sipuleucel-T (Provenge) done by consultants for Dendreon, the company who manufactures Provenge. They took the data from the al three of the phase III [...]
Understanding and deciding on appropriate treatments for men with advanced prostate cancer can be confusing. All the treatments come with side effects and one never knows what the benefits might be for an individual. Even with good clinical trials, men with advanced prostate cancer still need to navigate a most unclear path. Provenge, ever since [...]
I met with Dr. Kashif Shafique of the University of Glasgow who was the senior author of a research poster presented at the meeting. He and his colleagues look at the relationship between systemic inflammation and prostate cancer survival. Since there is some evidence that pre-treatment of systemic inflammation in men may be associated with [...]
As a follow up to my last post about the three posters that appeared at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium meeting I am going to share with you a video interview with Dr. Chadi Nabhan. Dr. Nabhan talks about his presentation about the phase III results of the Provenge IMPACT [...]
A group of researchers just reported positive results of a phase 3 trial showing that the addition of radiation therapy (RT) improves overall survival in men with locally advanced prostate cancer (T3 & T4) to androgen deprivation therapy (ADT) alone. The researchers used a sample of 1,057 men with locally advanced (T3 or T4) prostate [...]